Structural Comparative Modeling of Multi-Domain F508del CFTR
- PMID: 35327663
- PMCID: PMC8946492
- DOI: 10.3390/biom12030471
Structural Comparative Modeling of Multi-Domain F508del CFTR
Abstract
Cystic fibrosis (CF) is a rare genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), an epithelial anion channel expressed in several vital organs. Absence of functional CFTR results in imbalanced osmotic equilibrium and subsequent mucus build up in the lungs-which increases the risk of infection and eventually causes death. CFTR is an ATP-binding cassette (ABC) transporter family protein composed of two transmembrane domains (TMDs), two nucleotide binding domains (NBDs), and an unstructured regulatory domain. The most prevalent patient mutation is the deletion of F508 (F508del), making F508del CFTR the primary target for current FDA approved CF therapies. However, no experimental multi-domain F508del CFTR structure has been determined and few studies have modeled F508del using multi-domain WT CFTR structures. Here, we used cryo-EM density data and Rosetta comparative modeling (RosettaCM) to compare a F508del model with published experimental data on CFTR NBD1 thermodynamics. We then apply this modeling method to generate multi-domain WT and F508del CFTR structural models. These models demonstrate the destabilizing effects of F508del on NBD1 and the NBD1/TMD interface in both the inactive and active conformation of CFTR. Furthermore, we modeled F508del/R1070W and F508del bound to the CFTR corrector VX-809. Our models reveal the stabilizing effects of VX-809 on multi-domain models of F508del CFTR and pave the way for rational design of additional drugs that target F508del CFTR for treatment of CF.
Keywords: VX-809; comparative modeling; computational protein modeling; cystic fibrosis; pharmacological chaperones; protein folding disease; structure-based drug discovery.
Conflict of interest statement
The authors declare no conflict of interest.
Figures






Similar articles
-
VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1.Mol Biol Cell. 2013 Oct;24(19):3016-24. doi: 10.1091/mbc.E13-05-0240. Epub 2013 Aug 7. Mol Biol Cell. 2013. PMID: 23924900 Free PMC article.
-
Can two wrongs make a right? F508del-CFTR ion channel rescue by second-site mutations in its transmembrane domains.J Biol Chem. 2022 Mar;298(3):101615. doi: 10.1016/j.jbc.2022.101615. Epub 2022 Jan 21. J Biol Chem. 2022. PMID: 35065958 Free PMC article.
-
Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR.Biochem Pharmacol. 2020 Oct;180:114133. doi: 10.1016/j.bcp.2020.114133. Epub 2020 Jul 3. Biochem Pharmacol. 2020. PMID: 32628927
-
Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis.Acta Pharmacol Sin. 2011 Jun;32(6):693-701. doi: 10.1038/aps.2011.71. Acta Pharmacol Sin. 2011. PMID: 21642944 Free PMC article. Review.
-
Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function.Curr Drug Targets. 2016;17(11):1275-81. doi: 10.2174/1389450117666151209114343. Curr Drug Targets. 2016. PMID: 26648081 Review.
Cited by
-
Proteostasis landscapes of cystic fibrosis variants reveal drug response vulnerability.Proc Natl Acad Sci U S A. 2025 Apr 29;122(17):e2418407122. doi: 10.1073/pnas.2418407122. Epub 2025 Apr 22. Proc Natl Acad Sci U S A. 2025. PMID: 40261935
-
Benchmarking AlphaFold2 on peptide structure prediction.Structure. 2023 Jan 5;31(1):111-119.e2. doi: 10.1016/j.str.2022.11.012. Epub 2022 Dec 15. Structure. 2023. PMID: 36525975 Free PMC article.
-
CFTR Folding: From Structure and Proteostasis to Cystic Fibrosis Personalized Medicine.ACS Chem Biol. 2023 Oct 20;18(10):2128-2143. doi: 10.1021/acschembio.3c00310. Epub 2023 Sep 20. ACS Chem Biol. 2023. PMID: 37730207 Free PMC article. Review.
-
General trends in the effects of VX-661 and VX-445 on the plasma membrane expression of clinical CFTR variants.Cell Chem Biol. 2023 Jun 15;30(6):632-642.e5. doi: 10.1016/j.chembiol.2023.05.001. Epub 2023 May 29. Cell Chem Biol. 2023. PMID: 37253358 Free PMC article.
-
Dark nanodiscs for evaluating membrane protein thermostability by differential scanning fluorimetry.Biophys J. 2024 Jan 2;123(1):68-79. doi: 10.1016/j.bpj.2023.11.019. Epub 2023 Nov 20. Biophys J. 2024. PMID: 37978799 Free PMC article.
References
-
- Koch C., Høiby N. Pathogenesis of cystic fibrosis. [(accessed on 7 December 2020)];Lancet. 1993 341:1065–1069. doi: 10.1016/0140-6736(93)92422-P. Available online: https://www.sciencedirect.com/science/article/pii/014067369392422P. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical